Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may tell which oral cancer patients need more chemo

NCT ID NCT07296250

Knowledge-focused Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a blood test that finds circulating tumor cells (CTCs) can help decide if oral cancer patients need extra chemotherapy after standard treatment. About 100 patients who have completed surgery and chemoradiotherapy will be tested. If their CTC count is high, they will receive low-dose oral chemotherapy for up to a year. The goal is to see if this approach improves survival and creates a new standard for monitoring the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose oral chemotherapy
What this could lead to
If successful, this could provide a standard way to detect remaining cancer cells in the blood and guide personalized chemotherapy, potentially improving survival for oral cancer patients.
What could go wrong
This is a small, early-phase trial with only 100 participants. The approach is experimental, and it is not yet known if using CTC counts to guide treatment truly improves outcomes or causes side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 months to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants with Cancer: 1. Aged between 18 and 90 years. 2. Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC). 3. Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy. 4. Willing to continue follow-up visits at the hospital after completion of treatment. Exclusion Criteria: 1. Presence of psychiatric disorders. 2. Deemed unsuitable for participation by the attending physician. 3. Unwilling to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms lip and oral cavity carcinoma Mouth Neoplasms Neoplastic Cells, Circulating oral cavity squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer Oral cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Linkou Chang Gung Memorial Hospital

    RECRUITING

    Taoyuan City, 333423, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.